Try our beta test site
4 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND immunocytokine [TREATMENT]
Show Display Options
Rank Status Study
1 Completed Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell NHL
Condition: B-cell Non-Hodgkin Lymphoma
Intervention: Drug: DI-Leu16-IL2
2 Completed Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell NHL
Condition: B-cell Non-Hodgkin Lymphoma
Interventions: Drug: 0.5 mg/m2 DI-Leu16-IL2;   Drug: 1.0 mg/m2 DI-Leu16-IL2;   Drug: 2.0 mg/m2 DI-Leu16-IL2;   Drug: 4.0 mg/m2 DI-Leu16-IL2;   Drug: 6.0 mg/m2 DI-Leu16-IL2;   Drug: 8.0 mg/m2 DI-Leu16-IL2;   Drug: 10.0 mg/m2 DI-Leu16-IL2
3 Completed Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Biological: DI-Leu16-IL2 immunocytokine;   Biological: rituximab;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Genetic: reverse transcriptase-polymerase chain reaction
4 Completed EMD 521873 in Advanced Solid Tumors, MTD Finding
Condition: Non-Hodgkin Lymphoma
Intervention: Biological: EMD 521873

Study has passed its completion date and status has not been verified in more than two years.